Diabetic Macular Edema
Conditions
Keywords
Diabetic Macular Edema, Ocular Cytokines, aflibercept, ranibizumab
Brief summary
Diabetic macular edema refers to swelling (fluid accumulation) in the center of the retina. The retina is like the film of a camera and is located in the back of the eye. This condition can develop in diabetics where swelling results from leaking of fluid from the blood vessels of the eye, into the center of the retina, the macula. If left untreated, this can affect central. The current standard treatment for diabetic macular edema includes medications injected directly into the eye (intravitreal injections) and laser eye treatment. The drugs that are injected directly into the eye are known as anti-VEGF agents which help to reduce the leaking. This includes bevacizumab (Avastin®) and ranibizumab (Lucentis®). However, some patients do not respond well to these anti-VEGF treatments and will be given the option of switching to an another newer anti-VEGF medication, called aflibercept (Eylea®) that is approved to treat DME. A recent large study has demonstrated that aflibercept was as efficacious as other anti-VEGF therapies listed above and was even superior in patients with worse vision (Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015:150218140025008-150218140025008). The purpose of this study is to determine what factors affect the treatment response to aflibercept (amount of swelling reduction) for patients with diabetic macular edema, who were previously unresponsive to ranibizumab injections.
Interventions
BIOLOGICALaflibercept
EYLEA (aflibercept, solution for intravitreal injection) is a recombinant fusion protein consisting of portions of human Vascular Endothelial Growth Factor (VEGF) receptor 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.
Sponsors
Unity Health Toronto
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female aged 18 years or above * Presence of Non Proliferative Diabetic Retinopathy (NPDR) * Prior treatment with ≥ 6 intravitreal ranibizumab injections but no treatment in the last 4 weeks and less than 10% improvement in Central Macular Thickness on OCT scan and less than 1 line improvement in vision from baseline and less than 10% reduction in macular volume with Snellan Acuity 20/40 to 20/400 * Patients with DME with central macular thickness of 310μm or more on SD-OCT (cirrus) * Subjects with Type I or II diabetes mellitis * Willing and able to provide informed consent for participation in the study
Exclusion criteria
* Proliferative diabetic retinopathy in the study eye or PRP within the last 12 months or anticipated PRP in the next 6 months * Uncontrolled glaucoma * History of intraocular surgery within 3 months in the study eye * History of vitrectomy surgery * Laser treatment within 3 months of study eye * Vitreomacular traction, epiretinal membrane or any other maculopathy in the study eye * Prior intravitreal injection within the past 6 months * Known allergy to the study drug or fluorescein * History of stroke or AMI within 6 months of enrolment * Patients receiving dialysis for renal failure * Patients currently on systemic immunosuppression * Patients on two or more class of medication for glaucoma in study eye * Patients with tuberculosis * Patients who are pregnant. * Unwilling or unable to follow or comply with all study related procedures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in cytokine levels (picograms per mL) in patients with DME who were previously non-responders to ranibizumab (non-responders) between baseline aflibercept injection. | 1month, 2 months, 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Relation of baseline aqueous cytokine levels in patients with DME who were previously non-responders to ranibizumab (non-responders) to baseline Snellen BCVA in response to aflibercept | 3 months |
Contacts
Primary ContactRajeev Muni, MD
Backup ContactPhillip To
Outcome results
None listed